Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. Dezember 2013 06:10 ET | Quelle: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies

La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation of a "first in human" Phase-1 study of RP6530, a...
19. November 2013 06:35 ET | Quelle: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013

La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for its clinical lead, RP6530, a novel, dual Phosphoinositide-3...
09. September 2013 09:04 ET | Quelle: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany

La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke University...
06. September 2013 06:03 ET | Quelle: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013

La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the...
12. Juni 2013 05:08 ET | Quelle: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces a scientific presentation on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013

La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the therapeutic potential of its novel,...

Vorherige Seite